The New York City Rent Guidelines Board (RGB) voted 7-1 on Thursday to freeze the rent for rent-stabilized apartments.

A summary of the rent-stabilized apartment guidelines adopted on Thursday indicates that “Together with such further adjustments as may be authorized by law, the annual adjustment for leases for apartments shall be” 0% for one-year and two-year leases starting “on or after October 1, 2026, and on or before September 30, 2027.”

New York City Mayor Zohran Mamdani, whose prominent rent-freezing pledge marked a key plank of his Big Apple mayoral campaign last year, issued a statement hailing the board’s move.

“This is a historic victory for New York City tenants. After reviewing the data and hearing from New Yorkers across the city, the independent RGB has delivered a freeze on one-year leases, and the first-ever freeze on two-year leases in our city’s history. This is the relief that working people across our city deserve,” the mayor declared in the statement.

KEN GRIFFIN FIRES BACK AT MAMDANI, SAYS BUSINESS LEADERS MUST ‘FIGHT FOR THEIR CITY’

New York City Mayor Zohran Kwame Mamdani delivers a speech during a reception hosted at Gracie Mansion to celebrate Juneteenth in New York on June 16, 2026. (Selcuk Acar/Anadolu via Getty Images / Getty Images)

“I’m grateful for the board members’ thoughtful consideration of the data, including tenants’ ability to pay, cost of living and building operating costs. I’ll continue working to deliver a more affordable city by building and preserving affordable housing, lowering building operating costs like insurance, and ensuring tenants know their rights,” he added.

The board is stacked with six people appointed by Mamdani.

“Chantella Mitchell will serve as the Chair of the RGB; Sina Sinai, Lauren Melodia and Brandon Mancilla have been appointed as public representatives; Maksim Wynn will serve as an owner representative; and Adán Soltren has been reappointed as a tenant representative,” a February press release noted. “They join Arpit Gupta, Christina Smyth and Sagar Sharma on the nine-member board.”

MAMDANI-BACKED SOCIALIST WINS IN NEW YORK EXPOSE GROWING RIFT BETWEEN DEMOCRATIC ESTABLISHMENT, INSURGENT LEFT

Chantella Mitchell, chair of the Rent Guidelines Board, speaks prior to a vote by the Rent Guidelines Board in New York on Thursday, June 25, 2026. (Adam Gray/Bloomberg via Getty Images / Getty Images)

Smyth issued a statement announcing her immediate resignation on Thursday morning, prior to the board’s vote later that day.

“I am resigning because the process I was appointed to take part in is not administered the way the law requires. The Rent Guidelines Board has stopped being a fact-finding body. It has become a body that starts with an answer and vibe codes its way backward to justify it,” she asserted in a statement.

“This year’s RGB order was decided last year on the campaign trail. Then in February, the Mayor appointed six of the nine members of this board. This rebuilt board was required to deliver a rent freeze. Everything since has been theater. The hearings, the reports, the public comment, the data. None of it was ever going to change the result,” she declared.

SOCIALISM VS CAPITALISM: HOUSE DEMS CLASH OVER WHAT NY ELECTION RESULTS MEAN FOR PARTY

New York City Mayor Zohran Mamdani speaks during a primary-night watch party for NYC Congressional candidate Claire Valdez at 99 Scott Studio on June 23, 2026, in the East Williamsburg neighborhood of the Brooklyn borough in New York City. (Michael M. Santiago/Getty Images / Getty Images)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The board “is mandated to establish rent adjustments for the approximately one million dwelling units subject to the Rent Stabilization Law in New York City,” according to the city.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

But more importantly, Micron’s shift to long-term agreements with customers gives the group a more stable earnings profile, and makes it less vulnerable to sharp swings in demand, the head of technology research said. “These long-term agreements effectively put a ceiling and a floor on pricing and commit customers to taking supply, which smoothes what has historically been a highly cyclical market.”

The next era of mobile technology will turn everyday Americans into “walking cameras” as AI-powered smart glasses monitor everything they see and hear, according to Qualcomm CEO Cristiano Amon.

During an appearance on “Mornings with Maria,” Amon described a future in which ultra-fast 6G networks will allow smart glasses to stream information to AI models in real time. He said the shift could reshape both the technology industry and everyday life. 

“6G is going to transform all of us into walking cameras because we have the ability to, everything that we see, send it to AI models that will interact with us and get intelligence right away,” Amon said Friday. “And that’s an exciting new device category.”

MICROSOFT CEO HAS A WARNING ABOUT THE AI RACE

Qualcomm President and CEO Cristiano Amon delivered the keynote address at Computex 2024 on June 3, 2024, in Taipei, Taiwan. (I-Hwa Cheng/AFP via Getty Images / Getty Images)

Qualcomm is known for creating technology inside devices such as smartphones, allowing them to connect to the internet. Earlier this week, Qualcomm announced its latest partnership with Meta to support the company’s rapidly growing computing needs.

Amon pointed to smart glasses as a key device for the future, saying they allow people to interact with technology close to their faces while AI processes what users see and hear.

BESSENT LAYS OUT 5 PRINCIPLES GUIDING TRUMP ADMIN’S APPROACH TO ECONOMIC STATECRAFT

“There’s a very interesting thing about glasses, and Meta is correct, and there’s many other companies investing in this,” he said. 

Meta CEO Mark Zuckerberg wore a pair of Meta Ray-Ban Display AI smart glasses during the Meta Connect event on Sept. 17, 2025, in Menlo Park, California. Meta introduced its first smart glasses featuring a built-in display as part of its expanding we (David Paul Morris/Bloomberg via Getty Images / Getty Images)

“As we humans start to interact with the computers the way we interact with ourselves, glasses is a very important real estate because it’s close to our eyes, our ears, our mouth. And AI is [going to] see what we see, hear what we hear, read what we read. And then you have this intelligence very quickly.”

JEFF BEZOS PREDICTS AI WILL CREATE A LABOR SHORTAGE, NOT REPLACE HUMAN WORKERS ACROSS THE ECONOMY

Meta, Google and Apple have all invested in developing their own smart glasses, with newer models incorporating artificial intelligence. On Tuesday, Meta announced a new line of lower-cost AI glasses powered by the company’s AI technology, Muse Spark. 

A man tried on AI smart glasses during the Mobile World Congress in Shanghai on June 24, 2026. (Hector Retamal/AFP via Getty Images / Getty Images)

CLICK HERE TO GET FOX BUSINESS ON THE GO

Qualcomm has also expanded its focus into data centers and AI software. It introduced a new “Dragonfly C1000” central processing unit that it says Meta is using. The company also plans to acquire AI startup Modular.

“I was reading a lot of the analyst reports from Investor Day, and there’s one headline that really, I really liked it and it caught my attention. There’s a headline that said, ’This is not your father’s Qualcomm anymore,’” Amon said of the changes. “And I think that’s kind of the story of the company.”

Abbott Laboratories shares advanced more than 1.82 percent on Friday, closing at $94.90 after gaining $1.70, as investors responded positively to the company’s consistent growth in medical devices and diagnostics.

The gain reflected confidence in Abbott’s diversified healthcare portfolio spanning nutrition, diagnostics, medical devices and pharmaceuticals. The company has demonstrated resilience across economic cycles through its focus on essential healthcare products and innovation.

Abbott’s FreeStyle Libre continuous glucose monitoring system has driven significant growth in its diabetes care business. The technology has transformed diabetes management for millions of patients worldwide.

The company’s structural heart devices and electrophysiology products have shown strong performance as minimally invasive procedures gain adoption. Its broad product portfolio provides stability while high-growth segments fuel expansion.

Business Performance and Strategy

Abbott operates through four main segments: nutrition, diagnostics, established pharmaceuticals and medical devices. This diversification reduces reliance on any single market or product category.

Nutrition products, including Similac and Ensure, serve infant and adult populations with specialized formulations. The segment benefits from demographic trends and health consciousness.

Diagnostics solutions range from laboratory instruments to rapid testing kits. The company’s molecular and point-of-care testing capabilities support various healthcare settings.

Established pharmaceuticals focus on branded generic medicines in emerging markets. This business provides stable revenue with growth potential in developing economies.

Medical devices encompass cardiovascular, neuromodulation and diabetes care products. Technological innovation and clinical evidence support adoption of these therapies.

Innovation and Product Development

Abbott continues investing in research and development to advance its product pipeline. Recent innovations in glucose monitoring, heart valves and diagnostic testing have expanded treatment options.

The company’s focus on minimally invasive procedures aligns with healthcare industry trends toward reduced recovery times and lower costs. Its structural heart portfolio has achieved strong clinical results.

Diabetes care innovations have improved patient quality of life through continuous monitoring and automated insulin delivery systems. These technologies represent significant advances in chronic disease management.

Abbott’s diagnostic platforms support rapid and accurate testing across various medical conditions. Its ability to deliver reliable results in diverse settings enhances its value proposition.

Market Position and Competition

Abbott maintains strong positions in multiple healthcare categories through brand reputation and technological leadership. Its global presence supports revenue diversification across regions.

Competition varies by segment, with specialized players challenging in specific areas. Abbott’s broad portfolio and innovation track record provide competitive advantages.

International expansion, particularly in emerging markets, offers growth opportunities. The company’s experience navigating different regulatory environments supports successful market entry.

Supply chain management and manufacturing excellence ensure product availability and quality. Abbott’s global operations require careful coordination to maintain standards.

Investment Considerations

Abbott’s share price performance reflects investor appreciation for its consistent growth and dividend reliability. The company’s healthcare focus provides defensive characteristics in various economic environments.

The stock appeals to investors seeking exposure to medical technology and consumer healthcare trends. Its diversified business model and strong cash flow support positive long-term outlooks.

Risks include regulatory changes, competitive pressures and healthcare spending constraints. Abbott’s innovation pipeline and global reach provide some mitigation against these factors.

Analysts generally maintain positive views, citing the company’s execution capabilities and market opportunities. Continued growth in key segments could support further positive sentiment.

Industry Trends

The healthcare industry continues evolving with emphasis on personalized medicine, digital health and cost efficiency. Abbott’s focus on innovative medical devices and diagnostics aligns with these trends.

Aging populations in developed markets increase demand for chronic disease management solutions. Abbott’s diabetes and cardiovascular products address important needs in this demographic shift.

Emerging markets offer growth opportunities as healthcare infrastructure expands and middle classes grow. Abbott’s experience in these regions supports successful market penetration.

Technological convergence in healthcare creates opportunities for integrated solutions. Abbott’s combination of devices, diagnostics and pharmaceuticals positions it to participate in this evolution.

Future Outlook

Abbott’s strategic direction focuses on innovation, global expansion and operational excellence. Its ability to execute on these priorities will influence long-term performance.

The company continues investing in research and development while maintaining financial discipline. Its balance of growth and profitability supports sustainable success.

Investors will monitor upcoming financial results and product developments for signs of continued momentum. Management guidance will provide insight into execution priorities and market conditions.

The healthcare sector’s fundamental demand drivers remain strong. Abbott’s market leadership, innovation capabilities and global presence position it for sustained relevance and growth.

As the company advances its product portfolio and market reach, its contribution to healthcare improvement will expand. Abbott’s progress will be watched closely by patients, healthcare providers and investors worldwide.